PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million on June 15, 2023. In order to carry out the distribution as above, the Company's intention is, indicatively, that shareholders in Pharmiva shall receive twelve shares in Peptonic for each one share owned in Pharmiva in the form of merger consideration. However, the final merger consideration will be determined after the Companies have prepared and adopted a joint merger plan for the Merger. After completion of the transaction, Peptonic's holding is intended to amount to 85% of the number of shares in New Peptonic. harmiva's holding is intended to amount to 15% of the number of shares in New Peptonic. The joining of the two companies is planned to be completed through a merger under Swedish company law. The completion of the Merger is conditional upon, inter alia, that the Boards of Directors of each company resolve to complete the Merger and that the Merger is approved by an extraordinary general meeting in Pharmiva. The final decision on the merger will be made after union negotiations have been completed. As of August 21, 2023, Pharmiva shareholders has approved the transaction. As of October 12, 2023, Pharmiva applied for delisting of its shares from Nasdaq First North Growth Market, conditional on the completion of the merger with PEPTONIC.

Transaction is expected to close during the fourth quarter of 2023. Mangold Fondkommission AB is acting as financial advisor in connection with the planned Merger. Eversheds Sutherland Advokatbyrå AB is legal advisor in connection with the planned Merger.

PEPTONIC medical AB (publ) (NGM:PMED) completed the acquisition of Pharmiva AB (publ) (OM : PHARM) on November 21, 2023. As part of the transaction, all of Pharmiva's assets and liabilities have been transferred to Peptonic and Pharmiva has been dissolved.